Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $138.8 million.

  • Standard Biotools' Total Non-Current Liabilities fell 2722.61% to $138.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.8 million, marking a year-over-year decrease of 2722.61%. This contributed to the annual value of $139.6 million for FY2024, which is 1211.52% down from last year.
  • Standard Biotools' Total Non-Current Liabilities amounted to $138.8 million in Q3 2025, which was down 2722.61% from $131.2 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Total Non-Current Liabilities registered a high of $248.3 million during Q1 2022, and its lowest value of $121.5 million during Q1 2025.
  • Its 5-year average for Total Non-Current Liabilities is $168.9 million, with a median of $165.2 million in 2022.
  • Per our database at Business Quant, Standard Biotools' Total Non-Current Liabilities surged by 3728.59% in 2022 and then plummeted by 3848.46% in 2025.
  • Over the past 5 years, Standard Biotools' Total Non-Current Liabilities (Quarter) stood at $179.7 million in 2021, then fell by 11.22% to $159.6 million in 2022, then dropped by 0.48% to $158.8 million in 2023, then decreased by 12.12% to $139.6 million in 2024, then dropped by 0.56% to $138.8 million in 2025.
  • Its Total Non-Current Liabilities was $138.8 million in Q3 2025, compared to $131.2 million in Q2 2025 and $121.5 million in Q1 2025.